Skip to main content
Fig. 3 | Allergy, Asthma & Clinical Immunology

Fig. 3

From: Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score

Fig. 3

Proportion of participants reporting none or mild nasal and ocular symptoms during challenge. a Mean proportion of participants experiencing none or mild nasal and ocular symptoms was significantly greater in the loratadine group between 75 and 360 min. b Proportion of participants experiencing none or mild nasal and ocular symptoms remained higher in loratadine vs. placebo group at ≥ 75 min. Data are represented as mean ± SD (a only). ***P ≤ .001

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us